Comparing two drugs for low platelets from cancer treatment
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests if a new drug called Romiplostim N01 works better than the standard drug Interleukin-11 for raising low platelet counts caused by cancer treatments like chemotherapy or radiation. If you have low platelets from your cancer therapy, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You have a confirmed cancer diagnosis and are receiving chemotherapy, radiation, immunotherapy, or targeted therapy.
- Your platelet count is very low (between 10,000 and 75,000) from your cancer treatment.
- You are generally able to perform daily activities (ECOG score 0-2).
- Your doctor expects you to live at least 12 weeks and continue cancer treatment for at least one more cycle.
- You agree to use reliable birth control during the study if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called Romiplostim to help raise low platelet counts caused by leukemia treatment. It is for adults with leukemia whose platelets are below 50 and who may benefit from this therapy.
This trial tests a drug called Romiplostim N01 to help platelet levels recover faster in people with blood cancers who have had a cord blood transplant. It may reduce the need for platelet transfusions and lower bleeding risk.
This study tests a new version of a platelet-boosting medicine (romiplostim) for people whose platelets drop during cancer treatment. The goal is to see if it can safely raise platelet counts so you can continue your therapy.
This trial tests a new version of a drug called romiplostim to help raise platelet counts in breast cancer patients whose platelets drop because of chemotherapy. Raising your platelets may reduce the risk of bleeding and allow you to continue your cancer treatment.
This trial tests a drug called romiplostim for patients whose platelet counts stay very low (below 30) for a long time after chemotherapy, even after other treatments have failed. The goal is to see if romiplostim can help raise your platelet count to a safer level.
This trial tests a drug called romiplostim to prevent low platelet counts (a condition that raises bleeding risk) caused by chemotherapy in people with breast cancer. If you qualify, you may receive this drug to help keep your platelets at a safer level during future treatments.
Hear when a new CTIT: Cancer Therapy Induced Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.